問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2017-12-01 - 2018-12-20
Condition/Disease
Adjuvant treatment of Post- Resection Hepatocellular Carcinoma
Test Drug
Muparfostat (PI-88)
Participate Sites10Sites
Terminated8Sites
Study ended1Sites
Division of Others-
2008-05-01 - 2012-05-31
Participate Sites11Sites
Terminated11Sites
2007-03-01 - 2008-12-31
Participate Sites12Sites
Terminated12Sites
2008-03-01 - 2010-12-31
Participate Sites6Sites
Terminated6Sites
2007-12-25 - 2009-09-30
Participate Sites9Sites
Terminated9Sites
2004-09-01 - 2008-12-31
Participate Sites7Sites
Terminated7Sites
2007-09-01 - 2008-12-31
Participate Sites14Sites
Terminated14Sites
2007-05-01 - 2009-12-31
Study ended11Sites
2007-07-01 - 2010-12-31
Participate Sites3Sites
Terminated3Sites
2006-12-18 - 2010-09-07
Participate Sites13Sites
Terminated13Sites
全部
